Activity of Omadacycline Tested against Staphylococcus aureus from a Global Surveillance Program (2014)

RK FLAMM, PR RHOMBERG, MD HUBAND, DJ FARRELL
JMI Laboratories, North Liberty, IA, USA

ABSTRACT

Background: Omadacycline (OMC) is a new broad spectrum tetracycline-based antibiotic with an extended spectrum of activity compared to existing agents. This study evaluated the activity of OMC against a large collection of skin and skin structure isolates from the United States, Europe, and Canada.

MATERIALS AND METHODS

A total of 1051 hospital acquired MSSA (CA-MRSA, 980), community acquired MRSA (CA-MRSA, 41) and community acquired MSSA isolates (CA-MSSA, 150) from 2009-14 were collected from the US, Europe and Canada. Isolates were tested for susceptibility to OMC and comparator agents. MIC results were reported in the EU as was the MIC for Tigecycline.

RESULTS

Omadacycline: 2010-2014

- The MIC distribution for OMC against European CA-MRSA (1000 isolates), CA-MSSA (150), USA MSSA (980 isolates) and CA-MRSA (41) is shown in Table 1. OMC had an MIC50 of ≤0.12 mg/L and an MIC90 of 0.25 mg/L against all USA and European CA-MRSA isolates. OMC also had an MIC90 of ≤0.12 mg/L against USA and European CA-MSSA.

Omadacycline: Europe compared to North America

- The MIC distribution for OMC against European CA-MRSA (1000 isolates), CA-MSSA (150) and USA MSSA (980 isolates) and CA-MRSA (41) isolates is shown in Table 2.

REFERENCES